The Mission

RhinoLoop is a Swiss MedTech startup developing a breakthrough product to significantly improve the treatment of OSAS – Obstructive Sleep Apnea Syndrome. We provide significant convenience and effectiveness improvements over the current standard of care.

With a similar shape and invasiveness as a mandibular system, the Discontinuous Positive Airway Pressure – DPAP – provides the same performance as a CPAP, without electricity. Our patented double valve allows for generation of a 35% higher tidal volume than mandibular systems.

The DPAP technology generates a respiratory feedback effect between inspiration and expiration to induce a new work balance into the system during sleep time, that improves pulmonary ventilation of patients.

The treatment based on the DPAP eliminates most of the elements that cause patients to reject standar treatment with Continuous Positive Airway Pressure – CPAP.

Join us in this wonderful journey as an investor, clinical partner or industrial stakeholder.

Q&A - Did you know ?

Are patient compliant to CPAP ?

Did you know that 48% of CPAP patients stop their treatment within a year ?

What is crucial to the health of OSAS patients ?

Besides a regular medical supervision, one of the key bio-physical dimension is Tidal Volume; it refers to the amount of air inhaled or exhaled in a normal breath during quiet, resting breathing

What are the limitations of MAD - Mandibular Advancement Devices ?

MADs tend to be most effective in mild to moderate OSAS and primary snoring. In severe OSAS, they generally reduce the apnea–hypopnea index (AHI) but rarely normalize it